Abstract
High-sensitivity assays that accurately measure levels of the inflammatory biomarker C-reactive protein have been proposed for use in assessments of risk for cardiovascular disease (CVD). A growing body of evidence supports recommendations for these tests in selected asymptomatic individuals deemed to be at intermediate risk of CVD according to traditional risk-factor assessments and who do not already warrant chronic treatment with aspirin and statin therapy. Data suggests that these high-sensitivity assays should be used in combination with measurements of LDL-cholesterol levels to assist risk stratification of selected patients for prevention of CVD.
MeSH terms
-
Aged
-
Biomarkers / blood
-
C-Reactive Protein / analysis*
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / etiology*
-
Cardiovascular Diseases / prevention & control
-
Cholesterol, LDL / blood
-
Cost-Benefit Analysis
-
Diabetes Complications / blood
-
Diabetes Complications / etiology
-
Female
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hypertension / blood
-
Hypertension / complications
-
Inflammation Mediators / blood*
-
Male
-
Metabolic Syndrome / blood
-
Metabolic Syndrome / complications
-
Middle Aged
-
Predictive Value of Tests
-
Risk Assessment
-
Risk Factors
-
Risk Reduction Behavior
-
Secondary Prevention
-
Sensitivity and Specificity
Substances
-
Biomarkers
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Inflammation Mediators
-
C-Reactive Protein